Patents by Inventor Munir A. Hussain
Munir A. Hussain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170079999Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: December 6, 2016Publication date: March 23, 2017Inventors: Terrence C. DAHL, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLIYAI, Taiyin YANG
-
Patent number: 9545414Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: March 6, 2015Date of Patent: January 17, 2017Assignee: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCInventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20150174147Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: March 6, 2015Publication date: June 25, 2015Inventors: Terrence C. Dahl, Munir A. HUSSAIN, Robert A. LIPPER, Robert L. JERZEWSKI, Mark M. MENNING, Reza OLlYAI, Taiyin YANG
-
Patent number: 9018192Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: October 10, 2013Date of Patent: April 28, 2015Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20140037724Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicant: BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLCInventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Patent number: 8598185Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: GrantFiled: June 13, 2006Date of Patent: December 3, 2013Assignee: Bristol-Myers Squibb & Gilead Sciences, Inc.Inventors: Terrence C. Dahl, Munir A. Hussain, Robert A. Lipper, Robert L. Jerzewski, Mark M. Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20070099902Abstract: In accordance with this invention a novel pharmaceutical product containing efavirenz, emtricitabine and tenofovir DF are provided as a multicomponent unitary oral dosage form, component 1 comprising tenofovir DF (and, optionally, emtricitabine) and component 2 comprising efavirenz, wherein components 1 and 2 are in a stabilizing configuration. In preferred embodiments component 1 is made by dry granulation.Type: ApplicationFiled: June 13, 2006Publication date: May 3, 2007Inventors: Terrence Dahl, Munir Hussain, Robert Lipper, Robert Jerzewski, Mark Menning, Reza Oliyai, Taiyin Yang
-
Publication number: 20060057196Abstract: The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4 ?M to about 14 ?M, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and a mean area under the plasma concentration versus time curve from time zero to time infinity (AUC) of about 190 ?Mhour to about 470 ?Mhour.Type: ApplicationFiled: October 19, 2005Publication date: March 16, 2006Inventors: Munir Hussain, Julia Gao, Rajeshwar Motheram, David Gray
-
Publication number: 20050059719Abstract: An oral solid dosage formulation is provided which contains a Factor Xa inhibitor for which oral bioavailability is not reduced by co-administration of antacids, H2 antagonists and proton pump inhibitors. Such solid dosage formulation includes the Factor Xa inhibitor of the structure, a pharmaceutically acceptable carrier, and an acid component, such as tartaric acid, whereby upon ingestion of the oral solid dosage formulation, the acid component increases solubility of the Factor Xa inhibitor in the local environment of the dissolving solid dosage formulation resulting in an otherwise lower degree of supersaturation of the Factor Xa inhibitor in such environment, than if the acid were not present. The result is that precipitation of the Factor Xa inhibitor in the form of its insoluble free base is minimized during dissolution of the Factor Xa inhibitor thereby increasing its oral bioavailability.Type: ApplicationFiled: August 23, 2004Publication date: March 17, 2005Inventors: Sherif Badawy, Munir Hussain, Duxin Sun
-
Patent number: 6649187Abstract: The invention provides a method and device for administering an amine drug, such as [S-(R,S)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.Type: GrantFiled: February 12, 2002Date of Patent: November 18, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Munir A. Hussain, Arnold J. Repta
-
Publication number: 20030124186Abstract: The present invention provides an efavirenz tablet formulation which, when administered as a single dose to a subject, provides a mean maximum plasma concentration (Cmax) of about 4 &mgr;M to about 14 &mgr;M, a mean time of maximum plasma concentration (Tmax) of about 2 hours to about 5 hours, and a mean area under the plasma concentration versus time curve from time zero to time infinity (AUC) of about 190 &mgr;M·hour to about 470 &mgr;M·hour.Type: ApplicationFiled: November 26, 2002Publication date: July 3, 2003Inventors: Munir A. Hussain, Julia Zh. Gao, Rajeshwar Motheram, David B. Gray
-
Publication number: 20020160047Abstract: The invention provides a method and device for administering an amine drug, such as [S—(R,S)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.Type: ApplicationFiled: February 12, 2002Publication date: October 31, 2002Inventors: Munir A. Hussain, Arnold J. Repta
-
Patent number: 6214834Abstract: This invention relates to novel heterocycles which are useful as antagonists of the &agr;v&bgr;3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, to iontophoretic delivery of such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.Type: GrantFiled: March 27, 1998Date of Patent: April 10, 2001Assignee: Dupont Pharmaceuticals CompanyInventors: Prabhakar K. Jadhav, Douglas G. Batt, Munir A. Hussain, William J. Pitts, Arnold J. Repta
-
Patent number: 6185453Abstract: This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of integrin receptor antagonists in a controlled manner through the skin. Such integrin receptor antagonists include but are not limited to antagonists of the IIb/IIIa and &agr;v&bgr;3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising integrin inhibitors. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.Type: GrantFiled: June 18, 1997Date of Patent: February 6, 2001Assignee: DuPont Pharmaceuticals CompanyInventors: Munir A. Hussain, Arnold J. Repta
-
Patent number: 6095326Abstract: Packaging of disposable gloves with consumer tissue products in order: To provide first aid protection (disposable gloves) in every type of package of consumer tissue products, and To utilize the widely used consumer tissue products as a vehicle to deliver the disposable gloves to end user. A new package form for consumer tissue products and particularly facial tissue for containing infectious body fluids resulting from the said injuries comprising: a) Any form of consumer package tissue products, b) One or more protective disposable gloves, c) Said gloves package having dimensions allowing said package to be incorporated in any existing forms and shapes of consumer tissue products and particularly facial tissue.Type: GrantFiled: June 21, 1999Date of Patent: August 1, 2000Inventors: Maher N. Madhat, Munir A. Hussain
-
Patent number: 5961483Abstract: This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.Type: GrantFiled: June 18, 1997Date of Patent: October 5, 1999Inventors: Burton H. Sage, Carl Randolph Bock, Philip G. Green, Munir A. Hussain, Arnold J. Repta
-
Patent number: 4965066Abstract: There is disclosed intranasal pharmaceutical compositions of 3,3-disubstituted indolines useful for treating cognitive or neurological dysfunction in a mammal. Also disclosed is a method of treating cognitive neurological dysfunction in a mammal comprising administering intranasally to the mammal, the 3,3-disubstituted indolines of formula (I).Type: GrantFiled: June 6, 1989Date of Patent: October 23, 1990Assignee: E. I. Du Pont de Nemours and CompanyInventor: Munir A. Hussain
-
Patent number: 4757062Abstract: Substituted benzoate ester prodrugs of .beta.-estradiol and ethynyl estradiol are provided which have improved bioavailability and extended duration of action when administered orally.Type: GrantFiled: November 1, 1985Date of Patent: July 12, 1988Assignee: E. I. Du Pont de Nemours and CompanyInventors: Bruce J. Aungst, Munir A. Hussain
-
Patent number: 4673679Abstract: Aliphatic, aromatic, carbonate, carbamate, or sulfonate ester prodrugs of 3-hydroxymorphinans lack the bitter taste of the parent compounds and provide enhanced bioavailability of 3-hydroxymorphinans from buccal, nasal, and sublingual dosage forms.Type: GrantFiled: May 14, 1986Date of Patent: June 16, 1987Assignee: E. I. Du Pont de Nemours and CompanyInventors: Bruce J. Aungst, Munir A. Hussain
-
Patent number: D840707Type: GrantFiled: April 28, 2017Date of Patent: February 19, 2019Assignee: M Design Village, LLCInventor: Munir Hussain